Results 151 to 160 of about 69,722 (292)

Real‐world evaluation of clinical outcomes in Dutch patients with type 2 diabetes treated with oral semaglutide: A retrospective, observational cohort study using the PHARMO data network

open access: yesDiabetes, Obesity and Metabolism, EarlyView.
Abstract Aim A retrospective observational cohort study, in the Netherlands, evaluated clinical outcomes with oral semaglutide. Methods Glucagon‐like peptide‐1 receptor agonists (GLP‐1ra) naïve type 2 diabetes (T2D) patients who initiated oral semaglutide between 1 January 2020 and 31 December 2022 were identified from the PHARMO Data Network.
Abigail Postema   +7 more
wiley   +1 more source

Efficacy and safety of switching to ezetimibe 10 mg/rosuvastatin 2.5 mg in Korean patients with type 2 diabetes mellitus and dyslipidaemia: A multicentre, prospective study (EROICA study)

open access: yesDiabetes, Obesity and Metabolism, EarlyView.
Abstract Aims To evaluate the lipid‐lowering efficacy, safety, and adherence of switching from moderate‐ or low‐intensity statin monotherapy to ezetimibe 10 mg/rosuvastatin 2.5 mg in Korean patients with type 2 diabetes mellitus (T2DM) and dyslipidaemia.
Sangmo Hong   +10 more
wiley   +1 more source

Cardiorespiratory fitness and type 2 diabetes risk: A prospective cohort study with mediation analysis of biological aging in the UK Biobank

open access: yesDiabetes, Obesity and Metabolism, EarlyView.
Abstract Aims Higher cardiorespiratory fitness is associated with reduced type 2 diabetes mellitus (T2D) risk, but the underlying mechanisms remain incompletely understood. We investigated whether biological aging mediates the association between maximal oxygen uptake (VO2max) and incident T2D risk.
Xiangliang Liu   +7 more
wiley   +1 more source

A case of undetectable glycated hemoglobin (HbA1C) [PDF]

open access: yesQJM: An International Journal of Medicine, 2018
S N Hegde   +3 more
openaire   +2 more sources

Synergistic associations of metformin and GLP‐1 receptor agonist use with adiposity‐related cancer incidence in people living with type 2 diabetes

open access: yesDiabetes, Obesity and Metabolism, EarlyView.
Abstract Background Metformin and glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) may reduce the risk of adiposity‐related cancers in patients with type 2 diabetes (T2D). The potential synergistic effects of these treatments on cancer incidence remain unclear, considering their distinct biological mechanisms and their associated effects on body ...
Alex E. Henney   +6 more
wiley   +1 more source

Impaired CD4+ and T-helper 17 cell memory response to Streptococcus pneumoniae is associated with elevated glucose and percent glycated hemoglobin A1c in Mexican Americans with type 2 diabetes mellitus

open access: green, 2013
Perla J. Martinez   +8 more
openalex   +2 more sources

Home - About - Disclaimer - Privacy